Biovaxys Technology Corp 55336VAG5 Bond
BVAXF Stock | USD 0.05 0.01 11.78% |
Biovaxys Technology's financial leverage is the degree to which the firm utilizes its fixed-income securities and uses equity to finance projects. Companies with high leverage are usually considered to be at financial risk. Biovaxys Technology's financial risk is the risk to Biovaxys Technology stockholders that is caused by an increase in debt. In other words, with a high degree of financial leverage come high-interest payments, which usually reduce Earnings Per Share (EPS).
Biovaxys |
Given the importance of Biovaxys Technology's capital structure, the first step in the capital decision process is for the management of Biovaxys Technology to decide how much external capital it will need to raise to operate in a sustainable way. Once the amount of financing is determined, management needs to examine the financial markets to determine the terms in which the company can boost capital. This move is crucial to the process because the market environment may reduce the ability of Biovaxys Technology Corp to issue bonds at a reasonable cost.
Popular Name | Biovaxys Technology MPLX LP 4875 |
Equity ISIN Code | CA09076M1014 |
Bond Issue ISIN Code | US55336VAG59 |
S&P Rating | Others |
Maturity Date | 1st of December 2024 |
Issuance Date | 1st of June 2016 |
Coupon | 4.875 % |
Biovaxys Technology Corp Outstanding Bond Obligations
Dana 575 percent | US235822AB96 | Details | |
Volcan Compania Minera | USP98047AC08 | Details | |
Boeing Co 2196 | US097023DG73 | Details | |
HSBC Holdings PLC | US404280DR76 | Details | |
MPLX LP 4875 | US55336VAG59 | Details | |
MPLX LP 4125 | US55336VAK61 | Details | |
MPLX LP 52 | US55336VAL45 | Details | |
International Game Technology | US460599AD57 | Details | |
Morgan Stanley 3591 | US61744YAK47 | Details | |
Morgan Stanley 3971 | US61744YAL20 | Details | |
MGM Resorts International | US552953CD18 | Details | |
AerCap Global Aviation | US00773HAA59 | Details |
Understaning Biovaxys Technology Use of Financial Leverage
Biovaxys Technology's financial leverage ratio helps determine the effect of debt on the overall profitability of the company. It measures Biovaxys Technology's total debt position, including all outstanding debt obligations, and compares it with Biovaxys Technology's equity. Financial leverage can amplify the potential profits to Biovaxys Technology's owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if Biovaxys Technology is unable to cover its debt costs.
BioVaxys Technology Corp., a clinical biotechnology company, develops antiviral and anticancer vaccine platforms. BioVaxys Technology Corp. has a bioproduction agreement with WuXi Biologics Limited that produces SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH research collaboration with The Ohio State University, Wexner School of Medicine for BVX-0320 and agreement with Bioanalytical Systems, Inc. to conduct preclinical toxicology studies for its CoviDTH immunodiagnostic. BIOVAXYS TECHNOLOGY is traded on OTC Exchange in the United States. Please read more on our technical analysis page.
Currently Active Assets on Macroaxis
Other Information on Investing in Biovaxys OTC Stock
Biovaxys Technology financial ratios help investors to determine whether Biovaxys OTC Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biovaxys with respect to the benefits of owning Biovaxys Technology security.
What is Financial Leverage?
Financial leverage is the use of borrowed money (debt) to finance the purchase of assets with the expectation that the income or capital gain from the new asset will exceed the cost of borrowing. In most cases, the debt provider will limit how much risk it is ready to take and indicate a limit on the extent of the leverage it will allow. In the case of asset-backed lending, the financial provider uses the assets as collateral until the borrower repays the loan. In the case of a cash flow loan, the general creditworthiness of the company is used to back the loan. The concept of leverage is common in the business world. It is mostly used to boost the returns on equity capital of a company, especially when the business is unable to increase its operating efficiency and returns on total investment. Because earnings on borrowing are higher than the interest payable on debt, the company's total earnings will increase, ultimately boosting stockholders' profits.Leverage and Capital Costs
The debt to equity ratio plays a role in the working average cost of capital (WACC). The overall interest on debt represents the break-even point that must be obtained to profitability in a given venture. Thus, WACC is essentially the average interest an organization owes on the capital it has borrowed for leverage. Let's say equity represents 60% of borrowed capital, and debt is 40%. This results in a financial leverage calculation of 40/60, or 0.6667. The organization owes 10% on all equity and 5% on all debt. That means that the weighted average cost of capital is (.4)(5) + (.6)(10) - or 8%. For every $10,000 borrowed, this organization will owe $800 in interest. Profit must be higher than 8% on the project to offset the cost of interest and justify this leverage.Benefits of Financial Leverage
Leverage provides the following benefits for companies:- Leverage is an essential tool a company's management can use to make the best financing and investment decisions.
- It provides a variety of financing sources by which the firm can achieve its target earnings.
- Leverage is also an essential technique in investing as it helps companies set a threshold for the expansion of business operations. For example, it can be used to recommend restrictions on business expansion once the projected return on additional investment is lower than the cost of debt.